ELV stock forecast, quote, news & analysis

Key Takeaways

• Elevance Health shares traded near $428, roughly 3.8% higher than their closing level about 30 days earlier, a modest move within a broader recovery trend.
• The company reported second-quarter 2026 results that beat expectations and raised its full-year adjusted EPS guidance to at least $27.
• Margin pressure in Medicaid remains the central headwind, while Medicare Advantage performance and Carelon's expansion are key offsetting drivers.
• Third-quarter 2026 results are scheduled for release on October 21, 2026, with consensus estimates around $4.66 in EPS and $48.6 billion in revenue.
• Investors are watching margin trajectory, membership trends, and the scaling of the company's diversified services business.

Current Market Snapshot

Elevance Health (ELV) has traded in a relatively narrow but constructive range in recent weeks. The stock closed near $428 in mid-October 2026, up from roughly $412.56 about 30 days earlier — a gain of approximately 3.8% over that window. This modest appreciation reflects improving sentiment in the managed-care sector as investors weigh the company's ongoing efforts to stabilize government-sponsored plan margins against persistent cost-trend pressures.

The shares have recovered meaningfully from earlier-year lows, supported by a series of earnings beats and a clearer path toward margin normalization in 2027. Still, the near-term picture remains balanced, with elevated medical utilization in Medicaid offsetting progress in Medicare Advantage and growth across the company's Carelon services platform.

Elevance Health (ELV) Business Overview and Competitive Position

Elevance Health, formerly known as Anthem, is one of the largest health benefits companies in the United States. Through its affiliated Blue Cross and Blue Shield plans and other brands, the company serves approximately 104 million consumers across medical, pharmacy, behavioral, clinical, home health, and complex care solutions.

The business is organized into two primary segments. The Health Benefits segment includes Individual, Employer Group, Medicare, Medicaid, and Federal Employee Program offerings. The Carelon segment encompasses CarelonRx, the company's pharmacy benefit business, and Carelon Services, which provides behavioral health, home-based care, value-based care, and other clinical and administrative capabilities. This diversified model — combining insurance premium revenue with fee-based and product-based services — is a key competitive strength, and investors follow the stock closely as a bellwether for the broader managed-care industry alongside peers such as UnitedHealth Group (UNH) and Humana (HUM).

Recent Developments Driving ELV

Elevance Health's most recent earnings report, covering the second quarter of 2026, set a broadly constructive tone. The company reported adjusted earnings per share of $7.45, which exceeded consensus estimates, while operating revenue rose about 0.8% year over year to $49.8 billion. Management raised full-year 2026 adjusted EPS guidance to at least $27 and increased its operating cash flow outlook, citing better-than-expected Medicare Advantage performance and scaling in the Carelon business.

These positive signals have been balanced by persistent pressure in Medicaid, where the company has projected a full-year operating margin of approximately -1.75% amid concentrated utilization trends in behavioral health, specialty pharmacy, outpatient surgery, and emergency department care. Elevance has responded with disciplined plan design, planned market exits, and targeted technology investments — including AI-enabled analytics for earlier cost-trend detection and payment integrity — that management expects to support a return to at least 12% adjusted EPS growth in 2027.

Ahead of third-quarter results, consensus expectations call for earnings around $4.66 per share on revenue near $48.6 billion, reflecting year-over-year declines driven primarily by lower Medicaid and Individual membership. Analysts have adjusted price targets in both directions in recent months, reflecting the tension between improving Medicare Advantage and services momentum and ongoing government-plan margin headwinds.

Trending AI Robots

For traders seeking a more systematic approach to the market, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing automated strategies. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, but only the most relevant and highest-performing bots are highlighted in this section. These bots vary considerably in strategy, trading timeframe, and performance metrics, allowing users to evaluate approaches ranging from short-term swing trades to longer-horizon signals. The curated list provides a practical starting point for exploring how algorithmic tools analyze stocks like Elevance Health and other healthcare names.

2026 Outlook and What Investors Should Watch

Several factors are likely to shape Elevance Health's trajectory through the remainder of 2026 and into 2027. The most immediate is the third-quarter earnings report, where investors will scrutinize the Medicaid margin trend, benefit expense ratios, and any updates to full-year guidance. A key question is whether the company can demonstrate the expected sequential improvement in Medicaid margins and confirm 2026 as the trough for that business line.

Medicare Advantage execution remains another important watch item, given management's path toward at least a 2% operating margin and its conservative positioning for the 2027 selling season. The growth and profitability of Carelon — particularly CarelonRx and risk-based Carelon Services offerings — will also be closely monitored as a diversifying earnings driver. Broader regulatory developments, including potential changes affecting the Affordable Care Act exchanges and government reimbursement, could influence membership and earnings visibility. Finally, elevated medical cost trends across the sector remain a risk that could pressure margins if utilization stays above historical norms.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations